Overview

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-11-01

Target enrollment:

Participant gender:

Summary

This phase I/II trial tests the safety, best dose, and effectiveness of naxitamab in combination with sacituzumab govitecan in treating patients with triple-negative breast cancer (TNBC) that has spread from where it first started (primary site) to other places in the body (metastatic).

Phase:

PHASE1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Y-mAbs Therapeutics

Treatments:

naxitamab
sacituzumab govitecan